C6orf26 Inhibitors
Chemical inhibitors of C6orf26 can modulate its activity through various signaling pathways. Bisindolylmaleimide I, as a selective inhibitor of Protein Kinase C (PKC), disrupts the phosphorylation processes that are essential for the activation of many proteins, including C6orf26. This inhibition can lead to reduced activity of C6orf26 due to the suppression of PKC-mediated signaling. Similarly, staurosporine's broad kinase inhibition properties can impede multiple kinases that are responsible for phosphorylating C6orf26 or involved in its activation, thereby decreasing its functional activity. The calpain inhibitor ALLN targets proteolytic enzymes, which may be involved in the cleavage or modification of C6orf26, and its inhibition can result in decreased C6orf26 function. PD98059 and U0126, both inhibitors of MEK, can suppress the ERK pathway, which is potentially responsible for modulating C6orf26 activity. By preventing the activation of MEK, these inhibitors can impede the signaling cascade that might regulate the activity of C6orf26.
In addition to the aforementioned inhibitors, LY294002 and Wortmannin, both PI3K inhibitors, can attenuate the AKT pathway's role in regulating C6orf26. The downregulation of PI3K activity leads to a reduction in AKT signaling, which can decrease the activity of C6orf26. Rapamycin's inhibition of mTOR, a key signaling molecule for cell growth and proliferation, can indirectly affect the function of C6orf26 by disrupting the pathways it is involved in. SB203580 targets p38 MAP kinase, potentially diminishing C6orf26 activity if p38 MAPK is part of its regulatory pathway. Y-27632, by inhibiting ROCK, can affect the Rho/ROCK pathway that may influence the function of C6orf26. PD173074, which selectively inhibits FGFR, can prevent the activation of downstream signaling required for C6orf26's function. Lastly, SP600125, a JNK inhibitor, can reduce C6orf26 activity if JNK is involved in the regulatory pathways of C6orf26. Each of these inhibitors can alter the signaling mechanisms that control the functional activity of C6orf26 through different molecular interactions and pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a potent and selective inhibitor of Protein Kinase C (PKC), which can disrupt downstream signaling pathways that C6orf26 might be involved in. Inhibition of PKC results in suppressed phosphorylation of target proteins, potentially including C6orf26, thereby reducing its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective kinase inhibitor, known to inhibit a broad range of kinases. It could inhibit kinases that phosphorylate C6orf26 or are part of its activation cascade, thereby diminishing C6orf26's functional capacity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is upstream of the ERK pathway. As C6orf26 is involved in pathways regulated by ERK, PD98059's inhibition of MEK can result in diminished ERK activity, leading to decreased functional activity of C6orf26. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is upstream of the AKT signaling pathway. By inhibiting PI3K, LY294002 can suppress AKT activation, potentially leading to reduced activity of C6orf26, assuming C6orf26 is regulated by the AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and since mTOR is a central regulator of cell growth and proliferation, its inhibition can disrupt processes that C6orf26 is involved in. This can lead to a decrease in C6orf26 activity as a result of hindered downstream signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. If C6orf26 activity is regulated by the p38 MAPK pathway, inhibition by SB203580 would lead to reduced C6orf26 activity through the suppression of this pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). If C6orf26 function is influenced by the Rho/ROCK pathway, inhibition by Y-27632 would reduce C6orf26 activity by inhibiting this pathway. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a selective FGFR inhibitor. By inhibiting FGFR, PD173074 can inhibit downstream signaling that may be required for C6orf26 function, leading to reduced activity of the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If C6orf26 is regulated by pathways involving JNK, then inhibition by SP600125 would decrease C6orf26 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. C6orf26, if it operates within this pathway, would have reduced activity following U0126-mediated MEK inhibition. | ||||||